APPENDIX A

"CLEAN" VERSION OF EACH PARAGRAPH/SECTION/CLAIM
37 C.F.R. § 1.121(b)(ii) AND (c)(i)

CLAIMS (all are new):

17. A method of treating or preventing the rejection of transplanted organs, tissues or cells which comprises administering a chemokine receptor antagonist and a cyclosporin.

18. The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered simultaneously.

19. The method according to claim 17, wherein the chemokine receptor antagonist and cyclosporin are administered sequentially or separately.

20. The method according to claim 17, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

21. The method according to claim 17, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

22. The method according to claim 17, wherein the chemokine receptor antagonist is Met-RANTES.

23. The method according to claim 17, wherein the cyclosporin is cyclosporin A or a metabolite or synthetic analogue thereof.

24. The method according to claim 23, wherein the cyclosporin is cyclosporin A.

B1 25. The method according to claim 24, wherein the chemokine receptor antagonist is Met-RANTES.

26. The method according to claim 25, wherein the rejection treated or prevented is renal allograft transplantation rejection.

Sub D3 27. The method according to claim 24, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine or an amino-terminally extended RANTES.

29. The method according to claim 17, wherein the rejection treated or prevented is renal allograft transplantation rejection.

Sub D4 30. A pharmaceutical composition comprising at least one pharmaceutical acceptable excipient and the combination of a chemokine receptor antagonist and a cyclosporin.

31. The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

32. The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

33. The pharmaceutical composition according to claim 30, wherein the chemokine receptor antagonist is Met-RANTES.

34. The pharmaceutical composition according to claim 30, wherein the cyclosporin is cyclosporin A or a metabolite or synthetic analogue thereof.

Sub C2 35. The pharmaceutical composition according to claim 34, wherein the cyclosporin is cyclosporin A.

B1

36. The pharmaceutical composition according to claim 35, wherein the chemokine receptor antagonist is Met-RANTES.

Sub D5

37. The pharmaceutical composition according to claim 34, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine or an amino-terminally extended RANTES.